Aiforia Technologies Oyj

Equities

AIFORIA

FI4000507934

Software

Real-time Estimate Tradegate 03:40:11 2024-04-30 am EDT 5-day change 1st Jan Change
3.875 EUR -0.90% Intraday chart for Aiforia Technologies Oyj +6.83% +12.03%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Aiforia Technologies Oyj Appoints Richard Haworth to Its Scientific Advisory Board CI
Aiforia Technologies Oyj Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Aiforia Technologies Plc Releases Aiforia Studies A Software Module Offerering Ai-Assisted Image Analysis Workflow CI
Aiforia Partners with US Nonprofit to Commercialize AI Predicting Colorectal Cancer Recurrence MT
Aiforia Signs a Licensing Agreement with the Mayo Clinic for an AI Model That Improves Prediction of Colorectal Cancer Recurrence CI
Aiforia Technologies Enters Three-year Technology Deal with Italian Hospital MT
Aiforia Signs A Deal with an Italian Hospital in Catania CI
Aiforia Technologies Oyj Announces Appointment of Professor Inti Zlobec to Its Scientific Advisory Board CI
Aiforia Technologies plc Appoints Panu Kauppila as Chief Product Officer and A Member of the Management Team CI
Aiforia Technologies Plc Initiates Path to Secure its First Regulatory Approval in the United States CI
Aiforia Technologies Oyj Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Aiforia Signs Partnership With Orion for AI-based Image Analysis for Preclinical Research MT
Aiforia Technologies Oyj Signs A Major Deal with an Italian Regional Health Authority CI
First NHS Trust Signs Contract to Adopt Aiforia PD-L1 AI Model for Lung Cancer in Clinical Diagnostics CI
Aiforia Technologies plc Approves Executive Changes CI
Aiforia Technologies Plc Appoints Manuel Ahlsten as Vice President of Marketing CI
Aiforia Technologies Oyj Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Aiforia Technologies Wins AI Diagnostic Services Contract With 25 NHS Hospitals MT
Aiforia Technologies plc Receives A Contract Award to Provide AI Solutions for 25 NHS Hospitals of the Pathlake Plus Consortium in the UK CI
Kari Pitkänen, Director of Business Development at Aiforia Technologies Plc, to Retire by the End of December 2022 CI
Aiforia Technologies Oyj Appoints Thomas Westerling-Bui as Chief Commercial Officer of Americas and Member of the Management Team CI
Aiforia Technologies Plc's Member of the Board of Directors, John Sweeney, Resigns from the Board CI
Certain Shares of Aiforia Technologies Oyj are subject to a Lock-Up Agreement Ending on 8-JUN-2022. CI
Aiforia Technologies Launches Aiforia Community Platform CI
Aiforia Technologies Plc Expands its Portfolio of CE-IVD Marked Clinical Pathology Solutions with New AI Model for Breast Cancer Diagnostics CI
Chart Aiforia Technologies Oyj
More charts
Aiforia Technologies Oyj is a Finland-based company providing image analysis software utilizing artificial intelligence (AI). Aiforia’s business model is based on the development and utilization of AI models in the analysis of tissue and cell samples relating to medical research and diagnostics. The Company’s cloud-based deep learning artificial intelligence solutions aim to increase the speed, accuracy, and consistency of analyzing medical images across a wide range of fields. Aiforia's solutions aim to automate routine tasks and provide artificial intelligence to support the diagnostic workflow. The product offering consists of Aiforia Create, a solution with which the end user can develop their own AI model for any image analysis application simply by annotating images to train the AI model what to identify, quantify, or measure.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
3.91 EUR
Average target price
4.2 EUR
Spread / Average Target
+7.42%
Consensus
  1. Stock Market
  2. Equities
  3. AIFORIA Stock
  4. News Aiforia Technologies Oyj
  5. Aiforia Partners with US Nonprofit to Commercialize AI Predicting Colorectal Cancer Recurrence